1
|
Fang X, Cao J, Tao Z, Yang Z, Dai Y, Zhao L. Hydroxytyrosol attenuates ethanol-induced liver injury by ameliorating steatosis, oxidative stress and hepatic inflammation by interfering STAT3/iNOS pathway. Redox Rep 2023; 28:2187564. [PMID: 36932927 PMCID: PMC10026757 DOI: 10.1080/13510002.2023.2187564] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/19/2023] Open
Abstract
Objective: Hydroxytyrosol (HT) is a polyphenol with a wide range of biological activities. Excessive drinking can lead to oxidative stress and inflammation in the liver, which usually develop into alcohol liver disease (ALD). At present, there is no specific drug to treat ALD. In this paper, the protection effect of HT on ALD and the underline mechanism were studied.Methods: HepG2 cells were exposed to ethanol in vitro and C57BL/6J mice were fed with a Lieber-DeCarli ethanol liquid diet in vivo.Results: triglyceride (TG) level in serum and the expression of fatty acid synthase (FASN) were reduced significantly by the treatment with HT The acetaldehyde dehydrogenase (ALDH) activity was increased, the serum level of malondialdehyde (MDA) was decreased, catalase (CAT) and glutathione (GSH) were increased, suggesting that HT may reduce its oxidative damage to the body by promoting alcohol metabolism. Furthermore, according to the mRNA levels of tnf-α, il-6 and il-1β, HT inhibited ethanol-induced inflammation significantly. The anti-inflammatory mechanism of HT may be related to suppress the STAT3/iNOS pathway.Dissussion: Our study showed that HT could ameliorate ethanol-induced hepatic steatosis, oxidative stress and inflammation and provide a new candidate for the prevention and treatment of ALD.
Collapse
Key Words
- ADH, alcohol dehydrogenase
- ALD, alcohol liver disease
- ALDH, acetaldehyde dehydrogenase
- ALT, alanine aminotransferase
- AST, aspartate aminotransferase
- CAT, catalase
- COX2, cyclo-oxygen-ase2
- CYP2E1, cytochrome P450 2E1
- DMSO, Dimethyl sulfoxide
- DPPH, 2,2-Diphenyl-1-picrylhydrazyl
- FASN, fatty acid synthase
- GSH, glutathione
- HT, hydroxytyrosol
- HepG2
- Hepatic steatosis
- Hydroxytyrosol
- LDL, low density lipoprotein
- LPS, lipopolysaccharides
- Liver injury
- MDA, malondialdehyde
- NO, nitric oxide
- PPAR-γ, peroxisome proliferators-activated receptor
- ROS, reactive oxygen species
- SREBP-1c, sterol regulatory element-binding protein-1c
- STAT3, signal transducer and activator of transcription 3
- STAT3/iNOS pathway
- TC, total cholesterol
- TG, triglyceride
- alcoholic liver disease
- anti-inflammation
- anti-oxidation
- iNOS, inducible nitric oxide Synthas
Collapse
Affiliation(s)
- Xianying Fang
- Co-Innovation Center for Sustainable Forestry in Southern China, Nanjing Forestry University, Nanjing, People's Republic of China
- College of Chemical Engineering, Nanjing Forestry University, Nanjing, People's Republic of China
| | - Jiamin Cao
- Co-Innovation Center for Sustainable Forestry in Southern China, Nanjing Forestry University, Nanjing, People's Republic of China
- College of Chemical Engineering, Nanjing Forestry University, Nanjing, People's Republic of China
| | - Zhi Tao
- Co-Innovation Center for Sustainable Forestry in Southern China, Nanjing Forestry University, Nanjing, People's Republic of China
- College of Chemical Engineering, Nanjing Forestry University, Nanjing, People's Republic of China
| | - Zhiqing Yang
- Co-Innovation Center for Sustainable Forestry in Southern China, Nanjing Forestry University, Nanjing, People's Republic of China
| | - Yuan Dai
- Yanghe Distillery Co. Ltd, Suqian, People's Republic of China
| | - Linguo Zhao
- Co-Innovation Center for Sustainable Forestry in Southern China, Nanjing Forestry University, Nanjing, People's Republic of China
- College of Chemical Engineering, Nanjing Forestry University, Nanjing, People's Republic of China
| |
Collapse
|
2
|
Sharma RS, Harrison DJ, Kisielewski D, Cassidy DM, McNeilly AD, Gallagher JR, Walsh SV, Honda T, McCrimmon RJ, Dinkova-Kostova AT, Ashford ML, Dillon JF, Hayes JD. Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2). Cell Mol Gastroenterol Hepatol 2018; 5:367-398. [PMID: 29552625 PMCID: PMC5852394 DOI: 10.1016/j.jcmgh.2017.11.016] [Citation(s) in RCA: 140] [Impact Index Per Article: 23.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/14/2017] [Accepted: 11/30/2017] [Indexed: 02/07/2023]
Abstract
BACKGROUND & AIMS Nonalcoholic steatohepatitis (NASH) is associated with oxidative stress. We surmised that pharmacologic activation of NF-E2 p45-related factor 2 (Nrf2) using the acetylenic tricyclic bis(cyano enone) TBE-31 would suppress NASH because Nrf2 is a transcriptional master regulator of intracellular redox homeostasis. METHODS Nrf2+/+ and Nrf2-/- C57BL/6 mice were fed a high-fat plus fructose (HFFr) or regular chow diet for 16 weeks or 30 weeks, and then treated for the final 6 weeks, while still being fed the same HFFr or regular chow diets, with either TBE-31 or dimethyl sulfoxide vehicle control. Measures of whole-body glucose homeostasis, histologic assessment of liver, and biochemical and molecular measurements of steatosis, endoplasmic reticulum (ER) stress, inflammation, apoptosis, fibrosis, and oxidative stress were performed in livers from these animals. RESULTS TBE-31 treatment reversed insulin resistance in HFFr-fed wild-type mice, but not in HFFr-fed Nrf2-null mice. TBE-31 treatment of HFFr-fed wild-type mice substantially decreased liver steatosis and expression of lipid synthesis genes, while increasing hepatic expression of fatty acid oxidation and lipoprotein assembly genes. Also, TBE-31 treatment decreased ER stress, expression of inflammation genes, and markers of apoptosis, fibrosis, and oxidative stress in the livers of HFFr-fed wild-type mice. By comparison, TBE-31 did not decrease steatosis, ER stress, lipogenesis, inflammation, fibrosis, or oxidative stress in livers of HFFr-fed Nrf2-null mice. CONCLUSIONS Pharmacologic activation of Nrf2 in mice that had already been rendered obese and insulin resistant reversed insulin resistance, suppressed hepatic steatosis, and mitigated against NASH and liver fibrosis, effects that we principally attribute to inhibition of ER, inflammatory, and oxidative stress.
Collapse
Key Words
- ACACA, acetyl-CoA carboxylase alpha
- ACLY, ATP citrate lyase
- ACOT7, acetyl-CoA thioesterase 7
- ACOX2, acetyl-CoA oxidase 2
- ADRP, adipose differentiation-related protein
- AP-1, activator protein 1
- ATF4, activating transcription factor-4
- ATF6, activating transcription factor-6
- ApoB, apolipoprotein B
- BCL-2, B-cell lymphoma
- BIP, binding immunoglobulin protein
- C/EBP, CCAAT/enhancer-binding protein
- CAT, catalase
- CD36, cluster of differentiation 36
- CDDO, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid
- CES1G, carboxylesterase 1g
- CHOP, C/EBP homologous protein
- COL1A1, collagen, type I, alpha-1
- COX2, cyclooxygenase-2
- CPT1A, carnitine palmitoyltransferase 1a
- ChREBP, carbohydrate-responsive element-binding protein
- DGAT2, diacylglycerol acyltransferase-2
- DMSO, dimethyl sulfoxide
- ER, endoplasmic reticulum
- FASN, fatty acid synthase
- FXR, farnesoid X receptor
- GCLC, glutamate-cysteine ligase catalytic
- GCLM, glutamate-cysteine ligase modifier
- GPX2, glutathione peroxidase-2
- GSH, reduced glutathione
- GSSG, oxidized glutathione
- GSTA4, glutathione S-transferase Alpha-4
- GSTM1, glutathione S-transferase Mu-1
- GTT, glucose tolerance test
- H&E, hematoxylin and eosin
- HF, high-fat
- HF30Fr, high-fat diet with 30% fructose in drinking water
- HF55Fr, high-fat diet with 55% fructose in drinking water
- HFFr, high-fat diet with fructose in drinking water
- HMOX1, heme oxygenase-1
- IKK, IκB kinase
- IRE1α, inositol requiring kinase-1α
- ITT, insulin tolerance test
- IκB, inhibitor of NF-κB
- JNK1, c-Jun N-terminal kinase 1
- Keap1, Kelch-like ECH-associated protein-1
- LXRα, liver X receptor α
- MCD, methionine- and choline-deficient
- MCP-1, monocyte chemotactic protein-1
- MGPAT, mitochondrial glycerol-3-phosphate acetyltransferase
- MPO, myeloperoxidase
- MTTP, microsomal triglyceride transfer protein
- NAFLD, non-alcoholic fatty liver disease
- NAS, NAFLD activity score
- NASH
- NASH, nonalcoholic steatohepatitis
- NF-κB, nuclear factor-κB
- NOS2, nitric oxide synthase-2
- NQO1, NAD(P)H:quinone oxidoreductase 1
- Nrf2
- Nrf2, NF-E2 p45-related factor 2
- PARP, poly ADP ribose polymerase
- PCR, polymerase chain reaction
- PDI, protein disulfide isomerase
- PERK, PRK-like endoplasmic reticulum kinase
- PPARα, peroxisome proliferator-activated receptor α
- PPARγ, peroxisome proliferator-activated receptor γ
- PRDX6, peroxiredoxin 6
- PTGR1, prostaglandin reductase-1
- PTT, pyruvate tolerance test
- RC, regular chow
- SCAD, short-chain acyl-CoA dehydrogenase
- SCD1, stearoyl-CoA desaturase-1
- SFN, sulforaphane
- SHP, small heterodimer partner
- SLC7A11, solute carrier family 7 member 11
- SREBP-1c, sterol regulatory element-binding protein-1c
- TBE-31
- TGFβ, transforming growth factor beta-1
- TNF-α, tumor necrosis factor-α
- TXN1, thioredoxin-1
- TXNRD1, thioredoxin reductase-1
- UPR, unfolded protein response
- XBP1, X-box binding protein-1
- eIf2α, eukaryotic translation initiation factor 2A
- p58IPK, p58 inhibitor of the PKR kinase
- qRT-PCR, quantitative reverse transcriptase PCR
- α-SMA, alpha smooth muscle actin
Collapse
Affiliation(s)
- Ritu S. Sharma
- Division of Cancer Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom
| | - David J. Harrison
- School of Medicine, University of St Andrews, St Andrews, Scotland, United Kingdom
| | - Dorothy Kisielewski
- Division of Cancer Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom
| | - Diane M. Cassidy
- Division of Cancer Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom
- Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom
| | - Alison D. McNeilly
- Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom
| | - Jennifer R. Gallagher
- Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom
| | - Shaun V. Walsh
- Department of Pathology, Ninewells Hospital and Medical School, Tayside NHS Trust, Dundee, Scotland, United Kingdom
| | - Tadashi Honda
- Department of Chemistry and Institute of Chemical Biology & Drug Discovery, Stony Brook University, Stony Brook, New York
| | - Rory J. McCrimmon
- Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom
| | - Albena T. Dinkova-Kostova
- Division of Cancer Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom
| | - Michael L.J. Ashford
- Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom
| | - John F. Dillon
- Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom
| | - John D. Hayes
- Division of Cancer Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom
| |
Collapse
|